Neuropace INC 8-K filings

NeuroPace announced robust second quarter 2026 financial results, driven by significant RNS revenue growth, and has increased its full-year revenue guidance.

NeuroPace announced that its RNS System PMA Supplement for idiopathic generalized epilepsy (IGE) is not approvable in its current form, with the FDA requesting additional clinical evidence.

NeuroPace stockholders elected Class II directors and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for 2026.

NeuroPace reported first quarter 2026 financial results, with total revenue reaching $22.1 million and full-year revenue guidance increased to $99-$101 million.

NeuroPace, Inc. reported record third-quarter 2025 revenue of $27.4 million, a 30% increase year-over-year, and raised its full-year 2025 revenue and gross margin guidance.

NeuroPace reported record Q2 2025 revenue of $23.5 million and increased its full-year 2025 revenue guidance to $94-$98 million, driven by RNS System sales.

NeuroPace, Inc. announced a strategic leadership transition with the appointment of Patrick F. Williams as Chief Financial Officer, succeeding Rebecca Kuhn who will move into a Senior Strategic Advisor role.

NeuroPace, Inc. announced the successful election of Class I directors Joel Becker and Frank Fischer, and the ratification of PricewaterhouseCoopers LLP as its independent auditor for 2025, following its virtual Annual Meeting of Stockholders on June 6, 2025.

NeuroPace, Inc. has entered into a new $75 million credit facility with MidCap Financial, comprising a $60 million term loan and a $15 million revolving credit facility, while simultaneously repaying its existing $61.9 million secured indebtedness.

NeuroPace, Inc. announced preliminary one-year data from its NAUTILUS study for drug-resistant idiopathic generalized epilepsy, meeting safety endpoints and showing significant effectiveness in a key patient subgroup, while reaffirming its full-year 2025 financial guidance.

NeuroPace announced record quarterly revenue of $22.5 million for Q1 2025 and increased its full-year revenue guidance to $93-$97 million.

NeuroPace anticipates minimal impact from international trade tariffs on its operations and financial results and reaffirms its gross margin guidance for fiscal year 2025.

NeuroPace is strategically refocusing on its RNS System, leading to the termination of its distribution agreement with DIXI Medical for SEEG products, while reaffirming its 2025 revenue guidance and long-term financial goals.

NeuroPace announces strong Q4 2024 and full-year results, highlighted by record quarterly revenue and positive guidance for 2025, alongside a strategic public offering and repurchase of KCK holdings.

NeuroPace finalizes the repurchase of 5.3 million shares from KCK Ltd. and terminates its at-the-market (ATM) offering program, citing a strengthened balance sheet.

NeuroPace, Inc. has entered into an underwriting agreement for a public offering of 6,500,000 shares of common stock at $10.00 per share, with a portion of the proceeds used to repurchase shares from a significant stockholder.

NeuroPace, Inc. will repurchase all of its common stock held by KCK Ltd. in a privately negotiated transaction, funded by proceeds from a separate equity offering.

NeuroPace issues 2025 financial guidance, targeting revenue between $92 million and $96 million and gross margins of 73% to 75%, while also providing updates on clinical trials and product development.

NeuroPace, Inc. will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025, with a live audio webcast available.

NeuroPace reports preliminary unaudited revenue exceeding expectations for 2024 and appoints a new director to its board.

NeuroPace announced a 28% year-over-year revenue increase in Q3 2024, reaching $21.1 million, and raised its full-year revenue guidance to $78-$80 million.

NeuroPace announced a 17% increase in revenue for the second quarter of 2024 compared to the same period last year, and has raised its full-year revenue guidance.

NeuroPace, Inc. held its 2024 Annual Meeting of Stockholders, electing three Class III directors and ratifying PricewaterhouseCoopers LLP as its independent auditor.

NeuroPace announced a 25% year-over-year revenue increase in Q1 2024, driven by strong sales of its RNS System and DIXI Medical products, and extended its term loan maturity by one year.

NeuroPace announced record full-year 2023 revenue of $65.4 million, a 44% increase year-over-year, driven by strong sales of its RNS System.

NeuroPace's Chief Legal Officer, Irina Ridley, has resigned effective March 6, 2024, with a transition agreement in place.